Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Medical Specialties
Sector Health Technology
Employees 49
CEO Mr. Kenneth L. Londoner
Address 54 Wilton Road 2nd floor, Westport, CT 06880
Phone 1.230.409.5444
Website www.biosig.com

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
BioSig Technologies, Inc. -15.28% -42.86%
Phathom Pharmaceuticals, Inc. -7.69% -10.67%
Immunovant, Inc. -18.50% -75.12%
Omeros Corp. -10.34% 38.59%
Nkarta, Inc. 1.07% -13.64%

Statement Summary

as of 4:00 ET PM 09/27/2021
Total Assets (MRQ) 18.0 M
Total Liabilities (MRQ) 3.4 M
Shareholders’ Equity (MRQ) 14.6 M
Total Revenue (Annual) 207.0 K
Net Income (Annual) -7.7 M

Earnings And Estimates

as of 4:00 ET PM 09/27/2021

Current Qtr EPS Estimate -0.23
Current FY EPS Estimate -0.97
Long Term EPS Growth Estimate n/a
Next Expected Earnings Date //

BSGM vs S&P 500

as of 09/27/2021
Relative To
S&P 500
BSGM
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 09/27/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 -0.26 -0.24 -7.69%
03/2021 -0.19 -0.26 +36.84%
12/2020 -0.43 -0.35 -18.60%
09/2020 -0.45 -0.38 -15.56%
06/2020 -0.54 -0.72 +33.33%
03/2020 -0.24 -0.46 +91.67%
03/2019 -0.30 -0.30 0.00%
12/2018 -0.31 -0.33 +6.45%

Financial Strength

as of 4:00 ET PM 09/27/2021
Pre-Tax Margin -3.00
Net Margin 0.00
Operating Margin -3.00
Return On Equity -158.56
Return On Assets -130.41
Inventory Turnover (TTM) 0.99
Sales Growth (MRQ) n/a

Ratios

as of 4:00 PM ET 09/27/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 6.95
Price/Cash Flow (TTM) 0.00
Book Value (MRQ) 0.44
Quick Ratio (MRQ) 4.79
Current Ratio (MRQ) 5.01
Total Debt/Equity (MRQ) 0.02

Short Interest

as of 4:00 PM ET 09/28/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 09/27/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $-0.23 $-0.23
# of Estimates 1 1
High Estimate $-0.23 $-0.23
Low Estimate $-0.23 $-0.23
Year Ago EPS $-0.26 $-0.24
Year Over Year Growth Estimate -12.68% -3.97%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $-0.97 $-0.76
# of Estimates 1 1
High Estimate $-0.97 $-0.76
Low Estimate $-0.97 $-0.76
Year Ago EPS $-1.87 $-0.97
Year Over Year Growth Estimate -48.13% -21.65%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $-0.23 $-0.23 $-0.97 $-0.76
# of Estimates 1 1 1 1
High Estimate $-0.23 $-0.23 $-0.97 $-0.76
Low Estimate $-0.23 $-0.23 $-0.97 $-0.76
Year Ago EPS $-0.26 $-0.24 $-1.87 $-0.97
Year Over Year Growth Estimate -12.68% -3.97% -48.13% -21.65%

Insider Information Summary

as of 08/31/2021
% Insiders - 13.87%
% Remaining Total Shares - 86.13%
Current 1 Month
Net Insider Transaction 89.40 K 97.30 K
Shares Bought 89.40 K 97.30 K
Shares Sold 0.00 0.00

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

Recent Articles from TheStreet

Endo International Lead

Endo International Settles Louisiana Opioid Claims

Pharmaceutical company Endo International reaches a $7.5 million settlement with the Louisiana attorney general on all state government opioid claims.

People walk past the New York Stock Exchange on Wall Street. The benchmark S&P 500 Index rose to an all-time high on Wednesday. Photo: AFP

You're Better Off Ignoring Stock Market Indexes

James ‘Rev Shark’ Deporre says investors need to look past the broad market numbers to understand what’s really going on.

Sherwin Williams Cuts Guidance as Valspar Deal Gets Expensive

Sherwin-Williams Warns on Tight Supplies, Inflation

Company says suppliers seeing longer-term effects from Hurricane Ida.

A Bear Market in Stocks Is Coming, Peter Schiff Says

Cramer's Mad Money Recap Sept. 28: Inflation, Energy, Politics

From inflation worries to high natural gas prices and the chip shortage, Jim Cramer spotlights the issues weighing on the markets.

China's Credit Risks Are Down In Most Sectors, But Payment Delays Persist In Construction And Energy, Survey Finds

Tudor Perini is a 'Net/Net' Candidate

Real Money's Jonathan Heller looks at the numbers for construction firm.

cannabis

Cannabis Stocks Watchlist: U.S. MSO's, Aurora

Cannabis stocks were falling in tandem with overall markets, and could face pressure due to falling recreational revenue from Aurora Cannabis.

3. Micron Technology Inc. (MU)

Micron Technology Drops on Weak Outlook for First Quarter

Micron topped analysts' fourth quarter expectations but provided tepid outlook for the first quarter.

Ford Lead

Stock Market Today With Jim Cramer: Buy Ford

Jim Cramer discusses how to trade tech stocks during a selloff and Ford's EV plans.

NYSE Stock Market Wall Street Bull

Jim Cramer's Tale of Two Market Bulls

Fed's Powell and China's Xi have different goals but similar effects on markets.

Chewy Pet Food Lead

Chewy Lifted to Outperform; Wolfe Sees 'Strong Growth Ahead'

Wolfe Research upgraded Chewy to outperform, saying a drop in net new customer additions should reverse in fiscal 2022.